Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GABLOFEN vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Spasticity due to multiple sclerosis,Spinal cord injury,Cerebral palsy,Hiccups (off-label),Alcohol dependence (off-label),Trigeminal neuralgia (off-label)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic metabolism via deamination; minor CYP450 involvement. Approximately 15% is metabolized; 85% excreted unchanged in urine.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
30-35% bound to albumin.
Approximately 90–95% bound, primarily to albumin.
0.5-0.8 L/kg; indicates distribution into extracellular fluid and tissues.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 70-90%; intrathecal: near 100% (direct CSF delivery).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: reduce dose by 50%; GFR < 30 m L/min: avoid use.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Age 2-16 years: initial 5 mg orally twice daily, increase by 5 mg/day every 3 days to maximum 40 mg/day (10 mg four times daily) for weight < 50 kg; for weight ≥ 50 kg, use adult dosing.
Not established; safety and efficacy not studied in pediatric patients.
Initial 5 mg orally twice daily, increase slowly; maximum 40 mg/day; monitor for sedation and dizziness.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Abrupt discontinuation of intrathecal baclofen may precipitate severe withdrawal reactions including hyperpyrexia, altered mental status, rebound spasticity, and rhabdomyolysis, which can be life-threatening. Pump failure or dosage error may cause overdose or withdrawal.
None
Withdrawal reactions after abrupt cessation; renal impairment requiring dose adjustment; sedation and dizziness impairing ability to drive/operate machinery; increased risk of seizures in epileptic patients; exacerbation of psychotic disorders; respiratory depression when combined with CNS depressants.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to baclofen; concomitant use of opioids or other CNS depressants causing respiratory depression; intrathecal administration in patients with severe respiratory insufficiency or active infection at injection site.
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
No significant food interactions. Alcohol should be avoided due to additive CNS depressant effects. Grapefruit juice has no known interaction with baclofen.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: Limited data; animal studies show increased risk of neural tube defects and skeletal abnormalities at supratherapeutic doses. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal withdrawal syndrome (hypertonia, tremors, seizures) if used chronically. Avoid in all trimesters unless benefit outweighs risk.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Baclofen (active ingredient) is excreted into breast milk; M/P ratio approximately 0.5. Low relative infant dose (estimated 0.3-0.5% of maternal weight-adjusted dose). Monitor infant for sedation, hypotonia, and poor feeding. Caution with moderate to high maternal doses.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Increased renal clearance and volume of distribution in pregnancy may require dose escalation (typically 20-40% increase) to maintain efficacy. Taper gradually to avoid withdrawal; start at lowest effective dose and titrate cautiously. Postpartum: Reduce to prepregnancy dose within 2-4 weeks.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
GABLOFEN is a brand name for baclofen, a GABAB receptor agonist used for spasticity. Sudden withdrawal can cause serious hyperpyrexia, rigidity, and seizures; taper over 1-2 weeks. Renal dose adjustment required (creatinine clearance <30 m L/min: decrease dose or extend interval). Monitor for drowsiness, dizziness, and muscle weakness, especially when initiating therapy. For intrathecal use, pump refill intervals must be strict to avoid withdrawal.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Do not stop taking Gablofen suddenly; a gradual dose reduction is needed to avoid serious withdrawal reactions.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,May cause dizziness, drowsiness, or blurred vision; avoid driving or operating heavy machinery until you know how the drug affects you.,Take with food if gastrointestinal upset occurs.,Report any signs of infection at the pump site (pain, redness, swelling) if using intrathecal formulation.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GABLOFEN vs CHLORZOXAZONE, answered by our medical review team.
GABLOFEN is a Skeletal Muscle Relaxant that works by GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GABLOFEN and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GABLOFEN is: 10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GABLOFEN and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GABLOFEN is classified as Category C. First trimester: Limited data; animal studies show increased risk of neural tube defects and skeletal abnormalities at supratherapeutic doses. Second and third trimesters: Risk of . CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.